Agentic AI: The Next Step in Pharmaceutical Innovation

The pharmaceutical industry is huge: a global market worth roughly $1.76 trillion in 2024, projected to reach $3.15 trillion by 2032.^[1] It directly touches billions of lives, developing the treatments that define modern healthcare.

What those numbers hide is that the industry is struggling. It takes at least 10 years and an estimated $2 billion to develop a new drug.^[2] Timelines stretch across decades, and regulatory requirements keep getting more complex.

The global AI pharmaceutical market is projected to grow from $1.51 billion in 2024 to $16.49 billion by 2034.^[3] McKinsey estimates AI could create between $350 billion and $410 billion in annual value for pharmaceutical companies.^[4] Companies that work out how to use it first will set the pace.

The core operational challenges in pharma

For all its scientific advancement, progress is often held back by a distinct set of internal challenges. These create the bottlenecks that make it hard to scale operations, maintain compliance and innovate efficiently.

• Workflow fragmentation A drug's journey from concept to patient involves numerous specialized teams, from R&D and regulatory to manufacturing and commercial. Processes break down in the white space between them. Handoffs are manual, reliant on email, and lack real-time visibility, which produces delays and errors.

• Data readiness and quality Automation is useless without clean, reliable data, and an estimated 80% of this data is unstructured: text, images, notes. Garbage in, garbage out is a real barrier when data is spread across legacy systems, spreadsheets and PDFs in inconsistent formats.

• Interpretation-heavy tasks Many critical processes, from reviewing regulatory submissions to assessing marketing materials for compliance, rely on the subjective interpretation of highly trained experts. That reliance is what makes them hard to scale consistently.

• Domain nuance and the IT/business divide Regulatory Affairs, Legal and Market Access are governed by highly complex and specific rules. Generic IT solutions fail because they lack the domain understanding to navigate that nuance, so IT may not grasp the business problem while the functional team lacks the tools to solve it.

• AI expertise gap The inverse of the above. Business teams know their problems intimately but face a talent shortage: 44% of life science professionals cite a lack of skills as a primary barrier to AI adoption, and only 29% of roles in pharma and life sciences were filled internally in the first half of 2023, indicating heavy reliance on a scarce external pool.

Where agentic AI is making the biggest impact

What is needed is specialized, autonomous agents that automate entire workflows rather than single steps. SyncIQ deploys them across the major functions.

Regulatory affairs: compliance and submissions

Regulatory affairs is one of the most promising areas. With 80% of regulatory effort spent on document-heavy workflows, agents change how teams handle submission preparation, agency queries and compliance validation.

• Dossier scrutiny and authoring Agents review dossiers for gaps and inconsistencies, cross-check data, and draft documents against regulatory guidelines and templates.

• Regulatory query management When agencies send information requests, agents summarize context from the dossier and draft referenced responses, which shortens resolution times.

A mid-sized pharma company may be able to cut submission preparation time by 60% and accelerate time-to-market by 25% through the implementation of AI tools, according to PwC.^[8]

Manufacturing and quality assurance

Manufacturing and QA involve repetitive, rule-based processes that suit automation. Electronic batch manufacturing record reviews, deviation investigations and CAPA documentation are high-volume workflows where the value shows up immediately.

• Automated EBMR review Agents fetch and validate EBMR data against standard operating procedures, flag exceptions for human review, and generate structured summaries.

• Deviation and CAPA automation Workflows automate the investigation of deviations and out-of-specification results. Agents categorize issues, draft root cause analysis reports, and suggest corrective and preventive actions from historical data.

Market access: policy complexity at scale

Market access teams face perhaps the most complex data interpretation challenge in pharma. Managing relationships with payers, PBMs and government programs while tracking constant policy change is an ideal environment for agents.

• Policy and formulary intelligence Agents monitor payer and government policies continuously, providing real-time intelligence on formulary status and coverage changes.

• Automated reconciliation and dispute management Teams automate verifying formularies and reconciling rebate requests against contracts, which surfaces potential disputes while they are still manageable.

A mid-sized life sciences organization used AI to detect a 12% market share drop for a key drug significantly earlier than traditional analytics allowed, leading to faster corrective action.^[9]

Medical and commercial affairs

Medical Science Liaisons act as scientific and medical experts, bridging the company and external healthcare professionals. They are high-cost, high-skill resources that struggle to scale, so the work here is augmenting that expertise rather than replacing it.

• Intelligent preparation and response A brief generation agent creates pre-call HCP briefs by combining CRM and scientific data. A scientific response agent provides compliant answers to medical questions during meetings.

• Documentation and insight extraction A CRM logger auto-logs meeting summaries and action items, while insights from the field are structured for strategic analysis.

Why purpose-built agentic automation wins

The problem with most AI solutions in pharma is that they treat drug development like any other business process. Pharmaceutical work is not like managing inventory or processing invoices. When a regulatory specialist reviews an FDA submission, they are interpreting complex scientific data, reading nuanced guidance, and making judgment calls that determine whether a treatment reaches patients.

Generic chatbots fall flat because they lack that understanding. This is why purpose-built agentic platforms are winning where traditional tools have failed.

SyncIQ's Agent OS for life sciences provides the domain expertise, enterprise readiness and rapid deployment that pharmaceutical companies need, with implementations across regulatory affairs, market access, medical affairs and QA/manufacturing.

References

1. [1]Fortune Business Insights. Pharmaceutical Market Size, Share & Growth Report. fortunebusinessinsights.com
2. [2]Schneider Electric. From lab to launch: AI's impact on pharma drug development. blog.se.com
3. [3]Precedence Research. AI in Pharmaceutical Market Size, Share and Trends 2025 to 2034. precedenceresearch.com
4. [4]McKinsey & Company. The era of exponential improvement in healthcare? mckinsey.com
5. [5]Applied Clinical Trials. Harnessing Unstructured Data and Hospital Interoperability. appliedclinicaltrialsonline.com
6. [6]Beyond Bits and Algorithms: Redefining Businesses and Future of Work.
7. [7]AMS. Solving the Pharma and Life Sciences talent deficit. weareams.com
8. [8]PwC. Driving compliance and growth: AI-powered regulatory affairs. pwc.com
9. [9]Tellius. How AI Helps Market Access Teams Overcome Data & Analytics Struggles. tellius.com